JP2013500326A - 抗原性タウペプチドおよびその使用 - Google Patents

抗原性タウペプチドおよびその使用 Download PDF

Info

Publication number
JP2013500326A
JP2013500326A JP2012522292A JP2012522292A JP2013500326A JP 2013500326 A JP2013500326 A JP 2013500326A JP 2012522292 A JP2012522292 A JP 2012522292A JP 2012522292 A JP2012522292 A JP 2012522292A JP 2013500326 A JP2013500326 A JP 2013500326A
Authority
JP
Japan
Prior art keywords
peptide
tau
amino acid
seq
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012522292A
Other languages
English (en)
Japanese (ja)
Inventor
ジョセフ スミス Ｉｉｉ ジョージ
ネルソン ウィルズ ケネス
シャンチャオ チュ ジェフ
Original Assignee
ファイザー バクシーンズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー バクシーンズ エルエルシー filed Critical ファイザー バクシーンズ エルエルシー
Publication of JP2013500326A publication Critical patent/JP2013500326A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012522292A 2009-07-30 2010-07-20 抗原性タウペプチドおよびその使用 Pending JP2013500326A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30
US61/229,860 2009-07-30
PCT/IB2010/053313 WO2011013034A1 (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof

Publications (1)

Publication Number Publication Date
JP2013500326A true JP2013500326A (ja) 2013-01-07

Family

ID=42941871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012522292A Pending JP2013500326A (ja) 2009-07-30 2010-07-20 抗原性タウペプチドおよびその使用

Country Status (17)

Country Link
US (1) US20110177109A1 (enExample)
EP (1) EP2459214A1 (enExample)
JP (1) JP2013500326A (enExample)
KR (2) KR20120049900A (enExample)
CN (1) CN102596236B (enExample)
AR (1) AR078085A1 (enExample)
AU (1) AU2010277254B2 (enExample)
CA (1) CA2768346A1 (enExample)
CO (1) CO6612199A2 (enExample)
IN (1) IN2012DN00446A (enExample)
MX (1) MX2012001194A (enExample)
NZ (2) NZ618391A (enExample)
PE (1) PE20120817A1 (enExample)
RU (2) RU2518291C2 (enExample)
SG (1) SG177637A1 (enExample)
TW (2) TW201436804A (enExample)
WO (1) WO2011013034A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200094761A (ko) * 2017-12-04 2020-08-07 시아먼 이노디엑스 바이오테크 컴퍼니 리미티드 HBsAg의 정량적 검출을 위한 키트 및 방법
JP2021508673A (ja) * 2017-10-27 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ タウペプチド免疫原構築物
JPWO2022054795A1 (enExample) * 2020-09-08 2022-03-17
JP2022534406A (ja) * 2019-05-27 2022-07-29 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア タウの立体配座特異的エピトープ、それらに対する抗体、およびそれらに関連する方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010067262A1 (en) 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
PE20140218A1 (es) * 2010-10-07 2014-03-01 Ac Inmune S A Composicion farmaceutica
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
CA2841577C (en) 2011-07-11 2018-12-04 Indi Molecular, Inc. Akt-specific capture agents, compositions, and methods of using and making
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
JP6345655B2 (ja) * 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
US10195257B2 (en) * 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
CN115112898B (zh) 2015-07-15 2026-03-24 加州理工学院 Il-17f-特异性捕获剂、组合物以及使用和制造的方法
CN108135986B (zh) 2015-08-13 2022-07-29 纽约大学 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
US11719705B2 (en) 2017-06-15 2023-08-08 Indi Molecular, Inc. IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
EA202091012A1 (ru) 2017-10-25 2020-08-27 Янссен Фармасьютикалз, Инк. Композиции фосфорилированных тау-пептидов и их применения
CN108314737B (zh) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 一种重组蛋白及其制备方法和应用
CN110548135B (zh) 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
EP3861015A4 (en) * 2018-10-07 2022-11-23 The University of British Columbia CONFORMATION SPECIFIC EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES DIRECTED AGAINST AND METHODS THEREOF
CN113597431B (zh) * 2019-02-08 2025-02-21 普罗塞纳生物科学有限公司 识别Tau的抗体
CN113710269A (zh) 2019-02-08 2021-11-26 Ac免疫有限公司 磷酸化Tau肽疫苗的安全施用方法
WO2020186091A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
MA55902A (fr) 2019-04-24 2022-03-16 Ac Immune Sa Administration hétérologue de vaccins tau
WO2020236969A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
CN117751132A (zh) * 2020-08-07 2024-03-22 普罗塞纳生物科学有限公司 用于治疗阿尔兹海默氏病的tau疫苗
KR20240052854A (ko) * 2021-09-08 2024-04-23 조인트 스탁 컴퍼니 "바이오케드" Mhc 단백질 기반 이종 이량체를 포함하는 이중 특이적 항체
WO2023056369A1 (en) * 2021-09-29 2023-04-06 Janssen Pharmaceuticals, Inc. Method of safe administration of tau phosphopeptide conjugate
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用
WO2025227011A1 (en) * 2024-04-26 2025-10-30 Unm Rainforest Innovations Immunotherapy compositions and methods for treatment of tauopathy, neuroinflammation, and synaptic loss

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050383A1 (en) * 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers
JP2009132689A (ja) * 2001-01-19 2009-06-18 Cytos Biotechnology Ag 分子抗原アレイ

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (de) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Insektizid wirksames mittel zur bekaempfung von textilschaedlingen
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1993011231A1 (en) * 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
ATE249240T1 (de) 1998-02-12 2003-09-15 Immune Complex Corp Strategisch modifizierte hepatitis b kernproteine und ihre derivate
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
PT1119630E (pt) 1998-11-05 2006-05-31 Powderject Vaccines Inc Construcoes de acido nucleico para imunizacao genetica
PL192016B1 (pl) 1998-11-30 2006-08-31 Cytos Biotechnology Ag Kompozycja, sposób wytwarzania sztucznego, uporządkowanego i powtarzalnego układu antygenu, zastosowanie kompozycji oraz kompozycja szczepionki
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
WO2001077158A1 (en) 2000-04-07 2001-10-18 University Of Leeds Innovations Limited Hepatitis b core antigen fusion proteins
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1294893B1 (en) 2000-06-22 2006-03-15 UCB Pharma Limited Modification of hepatitis b core antigen
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
DE60336902D1 (de) * 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
NZ540620A (en) 2002-12-10 2009-03-31 Lorantis Ltd Stabilized immunogenic HBc chimer particles
UA93854C2 (ru) * 2003-12-17 2011-03-25 Вайет Ллк Иммуногенный конъюгат и способ его получения
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
CA2572427A1 (en) 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
ATE473758T1 (de) * 2006-04-13 2010-07-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Her-2/neu multipeptidimpfstoff
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
FR3058624B1 (fr) 2016-11-15 2018-12-07 L'oreal Brosse pour l'application d'un produit sur les cils et/ou les sourcils

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009132689A (ja) * 2001-01-19 2009-06-18 Cytos Biotechnology Ag 分子抗原アレイ
US20080050383A1 (en) * 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508673A (ja) * 2017-10-27 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ タウペプチド免疫原構築物
US11773148B2 (en) 2017-10-27 2023-10-03 United Neuroscience Tau peptide immunogen constructs
KR20200094761A (ko) * 2017-12-04 2020-08-07 시아먼 이노디엑스 바이오테크 컴퍼니 리미티드 HBsAg의 정량적 검출을 위한 키트 및 방법
KR102390761B1 (ko) 2017-12-04 2022-04-25 시아먼 이노디엑스 바이오테크 컴퍼니 리미티드 HBsAg의 정량적 검출을 위한 키트 및 방법
JP2022534406A (ja) * 2019-05-27 2022-07-29 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア タウの立体配座特異的エピトープ、それらに対する抗体、およびそれらに関連する方法
JPWO2022054795A1 (enExample) * 2020-09-08 2022-03-17
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
JP2025020455A (ja) * 2020-09-08 2025-02-12 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
JP7687699B2 (ja) 2020-09-08 2025-06-03 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物

Also Published As

Publication number Publication date
CN102596236B (zh) 2015-06-24
NZ618391A (en) 2015-07-31
WO2011013034A1 (en) 2011-02-03
TW201436804A (zh) 2014-10-01
RU2518291C2 (ru) 2014-06-10
KR20120049900A (ko) 2012-05-17
TW201106968A (en) 2011-03-01
EP2459214A1 (en) 2012-06-06
NZ598356A (en) 2014-06-27
CN102596236A (zh) 2012-07-18
TWI461209B (zh) 2014-11-21
US20110177109A1 (en) 2011-07-21
WO2011013034A4 (en) 2011-04-28
AU2010277254B2 (en) 2015-05-07
AR078085A1 (es) 2011-10-12
KR20130127547A (ko) 2013-11-22
PE20120817A1 (es) 2012-07-07
MX2012001194A (es) 2012-03-07
AU2010277254A1 (en) 2012-02-09
RU2014112002A (ru) 2015-10-10
RU2012102701A (ru) 2013-09-10
CA2768346A1 (en) 2011-02-03
SG177637A1 (en) 2012-03-29
CO6612199A2 (es) 2013-02-01
IN2012DN00446A (enExample) 2015-05-15

Similar Documents

Publication Publication Date Title
TWI461209B (zh) 包含抗原tau肽之免疫原及其組合物
JP5964280B2 (ja) ＩｇＥＣＨ３ペプチドワクチン
JP5859150B2 (ja) Ｐｃｓｋ９ワクチン
AU2002342891B2 (en) Antigen arrays comprising RANKL for treatment of bone disease
HK1173376A (en) Antigenic tau peptides and uses thereof
HK1163511B (zh) Ige ch3肽疫苗

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160222